Arnold Barnett's research specialty is applied mathematical modeling generally focused on problems of health and safety. His early work on homicide was presented to President Ford at the White House, and his analysis of US casualties in Vietnam was, among other things, the subject of a column by William F. Buckley. He has received the President's Award and the Expository Writing Award from INFORMS (1996 and 2001, respectively) and the President's Citation from the Flight Safety Foundation (2002) for “truly outstanding contributions on behalf of safety.” He has written op-ed pieces for The New York Times, The Wall Street Journal, The Boston Globe, and USA Today. Ten times he has been honored for outstanding teaching by students at MIT's Sloan School of Management; in 1992, Business Week described him as the “best” Sloan School faculty member. Dr. Barnett has testified in many legal proceedings as a statistical expert and an aviation-safety expert.

Dr. Frot is an economist with specialized expertise in applying quantitative analyses to competition, litigation, regulatory, and business intelligence issues. He advises firms in a wide range of industries, providing economic and econometric expertise on matters related to mergers, market concentrations, cartel investigations, and damages.

Over the years, he has performed numerous economic and econometric analyses in Phase I and Phase II mergers before the French Competition Authority and the European Commission, including Veolia Transport/Transdev, Jardiland/InVivo, Castel/Patriarche, Fnac/Nature & Découvertes, d’aucy/Triskalia, Lactalis/Nuova Castelli, Lactalis/Leerdammer, CMA CGM / Bolloré Logistics, Canal+/OCS, and Suez/Veolia. He has led case teams and performed economic analyses in several prominent horizontal and vertical cartel cases, as well as estimated damages in antitrust litigation and intellectual property matters. He has also assisted companies in modeling and implementing changes to pricing behavior.

His reports have been presented to the European Commission, the French Competition Authority, the Court of Appeals, the Conseil d’État (France’s highest administrative court), the Tribunal of Commerce of Paris, and regulators in the telecommunications, energy, transportation, and gambling sectors. Dr. Frot has published a number of articles in peer-reviewed journals and regularly speaks at international competition law and policy conferences.

Mr. Richardson has more than 30 years of experience as a senior executive at institutional asset management firms, most recently as executive director of client service and business development and member of the global management team at Impax Asset Management Group. Throughout his career, Mr. Richardson has been responsible for overseeing the management of institutional investment portfolios of fixed-income, listed equity, and private securities. During the final decade of his tenure as head of Impax’s North American business, these portfolios were managed with a particular focus on the role of environmental, social, and governance (ESG) factors in investment management decisions. He has consulted to public and private companies in numerous industries, including financial services and insurance, on investment, governance, and compliance matters. Mr. Richardson has had oversight of a full range of investment portfolios offered through different fund vehicles, including 40 Act funds, commingled funds, collective trust funds, limited partnerships, and segregated accounts. He has been responsible for client, asset, and revenue growth, as well as new product initiatives and M&A. Mr. Richardson testified at deposition and trial, and has contributed to articles on sustainable investments for media outlets such as the Financial Times, The New York Times, and CNBC. Prior to his work with Impax, he co-founded Global Energy Investors, a private equity infrastructure firm, and Dwight Asset Management, an institutional fixed-income investment firm that was subsequently acquired by Goldman Sachs. He serves as a member of the Global Leadership Council for the World Resources Institute, and as a member of the President’s Council for Ceres. Mr. Richardson is a CFA charterholder.

Dr. Sosa specializes in the economics of network industries, law and economics, and industrial organization. He has consulted to telecommunications and electric utility clients on a broad range of litigation and regulatory issues, including industry restructuring, technical standardization, operational and financial benchmarking, mergers and acquisitions, market power analysis, and competitive strategy. Dr. Sosa has served as an expert witness before several state and federal agencies, and has supported testifying experts in assessing the economic impacts of several high-profile mergers in the telecommunications industry. In other telecommunications work, Dr. Sosa has analyzed spectrum license acquisitions, wireless technology standards, and voice and data roaming markets. He has also consulted to telecommunications carriers in Latin America, Europe, and Asia on issues related to competition, regulation, and litigation. In addition, Dr. Sosa has performed damages and valuation analyses for clients in a broad range of litigation matters, including consumer class actions, intellectual property, employment, bankruptcy, and commercial contracts. He is a frequent public speaker and has published a number of articles in industry and professional journals, including Public Utilities Fortnightly, the Journal of Legal Studies, and the Michigan Telecommunications and Technology Law Review. He is a member of the American Economic Association and Federal Communications Bar Association. Before joining Analysis Group, he consulted to the California Energy Commission and Telcordia.

Professor Jagabathula specializes in AI and machine learning, AI infrastructure, business analytics, pricing, and operations. His research spans the AI value chain, from the compute, energy, and semiconductor constraints shaping AI development to the design and commercial effects of algorithmic decision systems, including pricing engines, recommendation systems, and substitution algorithms.

His work includes generative models of consumer shopping behavior, unstructured-text models for commodity-price forecasting, a benchmark of 23 frontier AI models on the CFA Level III exam, and reinforcement learning algorithms for dynamic pricing. He has worked in AI and machine learning for nearly two decades. Professor Jagabathula’s AI and machine learning research has appeared in NeurIPS, the Journal of Machine Learning Research, and IEEE Transactions on Information Theory, while his broader research includes publications in business journals such as Management Science and Marketing Science. He is a named inventor on three patents.

Professor Jagabathula is co-founder and CEO of Xcelsa Labs, a technology company focused on AI-driven semiconductor design. He previously co-founded Celect, which commercialized his machine learning research on consumer choice and was acquired by Nike. He also co-founded Velai, which uses AI models to extract financial price signals from news text. Professor Jagabathula served as chief scientist and scientific advisor to Arena AI, developing reinforcement learning algorithms for pricing. He has written for Fortune and Harvard Business Review and delivered more than 100 talks to academic and industry audiences.

Professor Jagabathula’s honors include the National Science Foundation CAREER Award, the MSOM Young Scholar Prize, the NeurIPS Outstanding Student Paper Award, and the Management Science Best Paper Award in Operations Management. He has also received NYU Stern’s Distinguished Teaching Award and recognition from Poets & Quants as a Top 40 Under 40 business professor.

Ms. Giacin is a corporate governance, compliance, and enterprise risk expert who evaluates organizational responses to compliance, financial, and integrity concerns, including in litigation. Her work focuses on escalation governance, whistleblower and open reporting systems, investigative oversight, and leadership engagement, with an emphasis on how organizations identify, assess, escalate and manage risk in crisis contexts, including across the transaction lifecycle. Ms. Giacin applies reporting data, trend analysis, and pattern recognition to evaluate emerging issues that arise in her work. She has served as an expert in litigation involving governance and escalation practices, including preparation of expert reports and deposition testimony, and has assessed risk-response frameworks, audit and board committee oversight, and the alignment of expertise with the magnitude of risk. Ms. Giacin consults to organizations on compliance investigations, governance frameworks, and risk-tracking systems designed to enhance transparency and support informed decision making. Previously, she led the global ombuds and open reporting program at General Electric, focusing on ethics, compliance, and enterprise-wide risk identification and resolution. She oversaw a network of more than 600 ombuds serving hundreds of thousands of employees worldwide and played a key role in resolving thousands of compliance matters annually, involving whistleblower, retaliation, employee relations, compliance and leadership issues.

Mr. Starfield specializes in the direction and management of large-scale cases involving complex economic and financial issues. For more than two decades, he has conducted economic analysis and managed case teams in support of leading academic experts in a range of cases, notably a number of matters involving complex securities, including residential mortgage-backed securities, collateralized debt obligations, and credit default swaps. In matters related to the Lehman bankruptcy, he supported multiple experts in assignments related to structured financial products, secured financing, collateral management, derivatives risk exposure, complex accounting topics, and the causes of Lehman's failure. He also managed case teams in the Enron-related litigations involving some of the major settlements emerging from the Enron bankruptcy. In addition, he has worked on a broad range of cases in the investment management area, including numerous matters involving alleged violations of Sections 10b-5 and 11, in which he provided management of many dimensions of financial and economic analysis, including market efficiency, loss causation and materiality, and damages. Mr. Starfield also worked with mutual fund companies, boards, and regulators in some of the most prominent market timing matters. He managed all aspects of financial and economic analysis in a fraudulent conveyance litigation involving one of the largest bank failures in US history, including identification and support of numerous academic expert witnesses who testified on the economics of the banking industry; conditions in real estate markets; the management, operation, and regulation of nationally chartered commercial banks and bank holding companies; and factors that led to bank failures.

He has conducted analyses and served as an expert in numerous matters involving commercial disputes, and also has significant experience in the valuation of large, closely held companies.

In his role as an expert, Mr. Starfield has developed economic and financial models; prepared testimony; developed, presented, and reviewed pretrial discovery; and evaluated the economic and financial analyses of opposing experts. He has provided support to successful testimony on numerous topics involving economics in both bench and jury trials. Outside of litigation, he has assisted clients in a variety of industries with development of business plans and financial projections, frequently involving the use of complex integrated financial models. Formerly a senior manager in the Dispute Analysis and Corporate Recovery Services group of Price Waterhouse, Mr. Starfield is a chartered accountant of South Africa, a member of the South African Institute of Chartered Accountants, and a member of the Association of Chartered Certified Accountants in the United Kingdom.

Professor Dranove's research focuses on problems in industrial organization and business strategy, with an emphasis on the health care industry. He has published nearly 100 research articles and book chapters, and is the author of six books, including The Economic Evolution of American Healthcare, Code Red, and the textbook The Economics of Strategy, which is used by leading business schools around the world. Professor Dranove regularly consults with leading health care organizations in the public and private sectors. He also has two decades of experience performing and testifying about economic analyses in both litigation and regulatory actions. Most recently, he testified on competition issues for the US Department of Justice in the agency’s effort to block a proposed merger of two commercial health insurers. Professor Dranove concluded that the proposed transaction likely would result in higher prices and less innovation. He also has served on the executive committee and board of directors of the Health Care Cost Institute. Professor Dranove is on the review board of numerous prominent industry journals; he is the editor of the International Journal of Health Economics and Management and an associate editor of the RAND Journal of Economics. He is an elected member of the National Academy of Medicine.

Professor Haas-Wilson is an expert in health care antitrust, including the competitive effects of hospital mergers and commercial health insurer mergers, the effects of vertical consolidation in health care markets, and the implications of physician networks on competition in the health care industry. She recently testified in Federal District Court in Idaho on behalf of plaintiffs, in an antitrust lawsuit alleging competitive harm from St. Luke’s Health System’s acquisition of a large independent physician practice. She has served as a consultant on antitrust issues to the Federal Trade Commission, the Massachusetts Attorney General, the California Department of Corporations, and numerous private entities. She also testified on behalf of the Federal Trade Commission in the matter of Evanston Northwestern Healthcare Corporation. Professor Haas-Wilson is the author of Managed Care and Monopoly Power: The Antitrust Challenge and coeditor of Uncertain Times: Kenneth Arrow and the Changing Economics of Health Care. Her research has appeared in the Journal of Political Economy, the Journal of Economic Perspectives, the Journal of Law and Economics, the Review of Economics and Statistics, and the Journal of Health Economics, among others.

Mr. Gold has more than 20 years of experience applying economics, finance, and statistics to litigation matters. He has been involved in all phases of the litigation process, from pretrial discovery to expert report and trial preparation. Mr. Gold has led teams supporting experts and assisted counsel on a variety of securities, commercial litigation, and intellectual property matters.

Mr. Gold has extensive experience consulting on securities matters, including analyzing market efficiency, estimating damages, conducting event studies, and analyzing potential settlements. He has also submitted expert declarations in civil and criminal securities fraud matters. His experience includes cases involving securities and financial derivatives such as swaps, structured notes, mortgage-backed securities, convertible preferred stock, and options. Mr. Gold has worked on antitrust matters involving the trading of securities, and he has conducted assessments of class certification in cases involving securities fraud, product liability, and false advertising, including analyzing whether liability or damages can be assessed using common proof. His work spans industries such as financial services, legal services, telecommunications, entertainment, health care, and oil and gas. He is the coauthor of “Federal Securities Acts and Areas of Expert Analysis” in the Litigation Services Handbook.

Mr. Beach has more than 30 years of experience valuing businesses; rendering fairness opinions; and negotiating, structuring, and closing mergers and acquisitions (M&A), financings, strategic alliances, and joint ventures. During his career, he has closed over 100 M&A transactions and over 100 financings for companies in the technology, health care, consumer products, and financial services industries. He has frequently served as an expert witness in complex litigation matters involving shareholder rights and valuation, and has testified several times in Delaware Chancery Court. As founder and president of Business Consulting Group, LLC, Mr. Beach oversees the firm’s valuation and advisory work for corporate transactions. Earlier in his career, Mr. Beach was head of corporate finance for KPMG and head of investment banking at Advest, Inc. In addition, he was president and co-founder of Boston Corporate Finance, a boutique investment banking firm focused on providing M&A, capital-raising, and general advisory services to global companies in the technology sector. He has served on the board of numerous companies and organizations, and has advised many companies on their strategic development and direction. Mr. Beach has been a guest lecturer at Harvard Business School, Cornell University, and Dartmouth College. He has been a certified public accountant and is a registered principal with the Financial Industry Regulatory Authority (FINRA).

Ms. Mulhern specializes in the application of economic principles to issues arising in complex business litigation. She has served as an expert witness on damages issues in commercial litigation matters, including intellectual property (IP) and breach of contract cases, providing testimony in various district and state courts. Ms. Mulhern’s intellectual property damages experience includes cases involving allegations of patent, copyright, and trademark infringement, as well as misappropriation of trade secrets; she has also provided expert testimony on these issues in Section 337 cases at the International Trade Commission (ITC). Before the ITC, she has testified on a variety of economic issues, such as domestic industry, remedy, bonding, commercial success, and public interest.  Ms. Mulhern’s litigation experience spans a variety of industries, including pharmaceuticals, medical devices, automotive, entertainment, consumer products, computer hardware and software, semiconductors, and telecommunications. In non-litigation matters, she has assisted clients in valuing intellectual property and other business assets in the context of strategic alliances and joint ventures. Ms. Mulhern has been recognized as among the top economic experts for IP matters by Intellectual Asset Management (IAM) in the IAM Patent 1000, which identifies leading patent professionals around the globe. She is a member of the American Economic Association and the Licensing Executives Society, and is a frequent writer and speaker on issues related to intellectual property valuation and damages assessment. 

Professor Rock is an expert in corporate law and corporate governance. He coauthored the book The Anatomy of Corporate Law: A Comparative and Functional Approach, and has published numerous articles on topics such as poison pills, politics and corporate law, hedge funds, corporate voting, proxy access, corporate federalism, and mergers and acquisitions. Prior to joining the NYU faculty, Professor Rock taught at the University of Pennsylvania Law School, where at various times he served as co-director of the Institute for Law and Economics, associate dean, senior advisor to the president, and provost and director of open course initiatives. He has held visiting professorships at NYU and Columbia University, and was a Fulbright Senior Scholar at Hebrew University. Prior to his academic career, Professor Rock worked as an attorney specializing in complex antitrust, corporate, and securities litigation. In January 2019, the American Law Institute named him Reporter for the Restatement of the Law, Corporate Governance.

An accomplished practicing physician, Dr. Jha is a global expert on public health and health policy. A leader in the area of pandemic preparedness and response, he was appointed White House COVID-19 Response Coordinator by the Biden administration. In this role, he led work to increase the development of and access to treatments and vaccines, improve testing and surveillance, facilitate major investments in indoor air quality measures, and put in place an infrastructure to respond more effectively to disease outbreaks. Dr. Jha’s research focuses on improving the quality and cost of health care delivery, using global health policies to address the challenges of the COVID-19 pandemic, and crafting better policy to improve health outcomes in the US and worldwide. He has published hundreds of research publications in peer-reviewed journals and has consistently been ranked in the top 1% of most cited researchers. Previously, Dr. Jha was a dean and professor at the Brown School of Public Health and, before that, a professor at the Harvard T.H. Chan School of Public Health and Harvard Medical School. He also served as the faculty director of the Harvard Global Health Institute and held various leadership roles at the Harvard T.H. Chan School of Public Health. Dr. Jha currently serves as a member of the BMJ international advisory board and has been a member of the National Academies of Sciences, Engineering, and Medicine since 2013.

Professor Hart is a leading expert in contract theory, the theory of the firm, and corporate finance. In 2016, he and Professor Bengt Holmström were awarded the Nobel Prize in Economics for their work in contract theory. Professor Hart’s research centers on the roles that ownership structure and contractual arrangements play in the governance and boundaries of corporations. His recent work involves determining how parties can write better contracts, as well as how a new model of corporate governance can better incorporate the importance shareholders place on nonfinancial criteria.

Professor Hart has consulted to businesses and government entities, and provided expert testimony on contract and governance disputes in which he has evaluated the business purpose and economic substance of special purpose entities. As an expert on behalf of Qualcomm in Apple v. Qualcomm, he provided guidance on the optimal structure of contracts, and why and when they should be enforced. His book Firms, Contracts, and Financial Structure is a leading work in the fields of contract theory and corporate finance. He has published widely in peer-reviewed journals and contributed to the Financial Times and The Wall Street Journal. Professor Hart is a member of the IGM (Initiative on Global Markets) Economics Experts Panel of The University of Chicago Booth School of Business, and is affiliated with the Program on Corporate Governance at Harvard Law School’s John M. Olin Center for Law, Economics, and Business. He is a past president of the American Law and Economics Association.

Ms. Okie has conducted economic and financial analyses and managed case teams in support of academic and industry experts across engagements in securities and antitrust litigation, regulatory investigations, bankruptcy matters, arbitrations, and general commercial litigation. Her experience spans a wide variety of sectors and has included fact and expert discovery, class certification, liability and damages, and trial. Her antitrust work includes civil and criminal litigation surrounding a variety of alleged anticompetitive conduct and analyses of competition issues across a range of industries. Ms. Okie has worked on a number of matters at the intersection of antitrust and financial services, including alleged anticompetitive conduct related to foreign exchange rates, municipal bond markets, and financial product trading. She has assessed alleged misrepresentations and omissions in the underwriting of securities, including issues surrounding loss causation, falsity, materiality, and buy-side and sell-side due diligence; analyzed valuation issues in mergers and acquisitions; and evaluated REIT market corporate governance and industry dynamics. In the energy sector, Ms. Okie has estimated damages associated with failed projects; valued rights-of-way; and supported clients involved in market manipulation investigations by the US Department of Justice (DOJ), the Commodity Futures Trading Commission (CFTC), the Federal Energy Regulatory Commission (FERC), and state agencies. She has evaluated trading data, market power, and other competitive issues in oil, natural gas, propane, and electricity markets. Ms. Okie has published on many energy; environmental; and environmental, social, and governance (ESG) topics and authored white papers and reports for foundations, regional transmission organizations, and industry organizations. Ms. Okie has served as vice-chair of the Insurance and Financial Services Committee of the American Bar Association’s Antitrust Law Section.

Professor Blanchard’s research combines experiments with observational data analyses to study how consumers make complex decisions about finance and technology. He serves as a marketing and research expert in commercial litigation and advises financial services and technology companies on business strategies and research. Professor Blanchard is the director of Georgetown’s M.B.A. Certificate in Consumer Analytics and Insights program, and he teaches courses on research design, surveys, and quantitative analyses to undergraduate, graduate, and executive education program students. He has been named among the best 40 business professors under 40 by Poets&Quants, and a Young Scholar by the Marketing Science Institute. 

Professor Blanchard is an associate editor of the Journal of Marketing Research, the Journal of Consumer Research, and the International Journal of Research in Marketing, and he has published articles in a number of prominent marketing journals. Professor Blanchard’s research and perspectives on consumer finances and technology have been featured in media outlets such as Forbes, Fortune, Harvard Business Review, NerdWallet, The New York Times, Marketplace, and NBC News. In addition to serving on the Georgetown faculty, he served as a member of the American Marketing Association’s Academic Council, and held visiting positions at Dartmouth College and Columbia University.  

Mr. Gorin has more than 30 years of experience as a strategy and economic consultant with deep expertise in the health care, chemicals, oil and gas, agriculture, and automotive industries. He leads large, complex engagements in antitrust matters, health care strategy, and large commercial litigation cases, providing direct leadership at every stage of engagement, from strategy to implementation. In addition to his own expert work, Mr. Gorin regularly identifies and collaborates with leading academic and industry affiliates. Mr. Gorin's unique experience across industries and practices allows him to leverage his complementary strategic, economic, and specific subject matter expertise to provide pragmatic solutions to address clients' complex business and legal challenges. 

Mr. Gorin's work in antitrust and competition cases has included the analysis of alleged anticompetitive behavior and the evaluation of the competitive impact of mergers and acquisitions in strategic, regulatory, and litigation contexts. In these cases, Mr. Gorin has defined and analyzed relevant markets, assessed potential or past competitive impact, simulated the outcome of mergers and acquisitions in the marketplace, and evaluated potential antitrust remedies. As a leading expert in Analysis Group's Health Care Strategy practice, Mr. Gorin works with diagnostic innovators and manufacturers to develop acquisition and growth strategies, create plans to achieve favorable coverage and reimbursement in the United States and international markets, and design and implement evidence development strategies to support coverage and reimbursement goals. In commercial litigation cases, he regularly leads teams and experts to support clients in matters related to liability and damages, such as valuation, economic harm, accounting, corporate governance, and organizational performance and culture. 

Prior to joining Analysis Group, Mr. Gorin was a partner in the worldwide Energy, Chemicals, and Pharmaceuticals Group at Booz, Allen & Hamilton, Inc.

Professor Happe is a licensed pharmacist with more than 20 years of experience as an academic and a senior executive across health care consulting, pharmaceutical research, managed care, and graduate education. Her areas of expertise include pharmacy benefit management, drug coverage policy, pricing and payment flows throughout the supply chain, pharmacoeconomics, health outcomes research, and epidemiology. Prior to joining the University of Florida, Professor Happe was the chief pharmacy officer at Humana Pharmacy Solutions, where she directed the outcomes research and policy teams and led the enterprise opioid task force. She also served as Humana’s director of research and publications, contributing to more than 70 articles published in peer-reviewed journals. Professor Happe is editor in chief of the Journal of Managed Care & Specialty Pharmacy.

Professor Keller is an expert on marketing management, branding, and brand equity. His research focuses on improving marketing strategies through an understanding of consumer behavior, as well as on the design, implementation, and evaluation of integrated marketing communication programs. Professor Keller has served as brand advisor to a number of large corporations, including Accenture, American Express, Disney, Ford, Intel, Levi-Strauss, L.L. Bean, Nike, Procter & Gamble, and Samsung. He has published over 120 papers in peer-reviewed journals such as the Journal of Marketing, the Journal of Marketing Research, and the Journal of Consumer Research. He also authored the widely used textbooks Marketing Management (with Philip Kotler) and Strategic Brand Management. Professor Keller has received numerous awards for his research accomplishments, and has conducted marketing seminars for executives in a variety of forums. He previously held faculty positions at the University of California, Berkeley; Stanford University; and the University of North Carolina at Chapel Hill.

Dr. Strombom is an expert in applied microeconomics, finance, and quantitative and statistical analysis. He provides assistance to attorneys in all phases of pretrial and trial practice, prepares economic and financial models, and provides expert testimony in litigation and public policy matters. Dr. Strombom has conducted assessments of class certification, liability, and damages issues in cases involving antitrust, breach of contract, ERISA, false advertising, intellectual property, labor and employment, product liability, securities, and general commercial disputes.

Prior to joining Analysis Group, Dr. Strombom was Executive Vice President of a middle-market merger and acquisition firm, where he managed a financial and market research organization that provided valuation and consulting services to over 500 privately held companies annually. Previously, he was Consulting Manager at Price Waterhouse, where he provided litigation support and value enhancement consulting services, and Senior Financial Analyst at the Tribune Company, where he evaluated capital projects and acquisition candidates.

Professor Rossi specializes in fintech, household and personal finance, machine learning, and asset pricing, with a strong focus on leveraging advanced analytics to improve financial decision making. His research has included investigations of how robo-advisors can help individuals make better financial decisions and how machine learning can be used to predict stock market returns. Professor Rossi has contributed chapters to several books, including the Handbook of Financial Decision Making and Machine Learning in Financial Markets: A Guide to Contemporary Practice. His articles have appeared in peer-reviewed journals such as the Journal of Financial Economics, Management Science, The Review of Financial Studies, and The Journal of Finance and been cited in media outlets such as The Wall Street Journal, Kiplinger, Forbes, and CNN. A prolific speaker, Professor Rossi has given keynote addresses and presented at numerous conferences. Earlier in his career, he was an associate professor at the University of Maryland’s Robert H. Smith School of Business and an economist at the Board of Governors of the Federal Reserve System. Professor Rossi is a visiting fellow in economics studies at the Brookings Institution. He also serves on the Economic Advisory Committee at the Financial Industry Regulatory Authority (FINRA) and is a member of the American Economic Association, the American Finance Association, and the European Finance Association.

Laura O’Laughlin applies rigorous economic and marketing research to complex litigation, regulatory, and business strategy questions. Her broad economic consulting practice spans antitrust and competition, intellectual property, data privacy, consumer protection, class certification, technology, commercial disputes, and labor and employment matters. Ms. O’Laughlin has particular expertise in consumer surveys and other empirical research addressing consumer perceptions, purchasing behavior, false advertising, brand reputation, defamation, and trademarks and consumer confusion. She has testified as an expert witness in deposition and trial and led multidisciplinary teams supporting academic, technical, and industry experts throughout the US and Canada.

Ms. O’Laughlin’s work in emerging technology matters includes data privacy litigation involving consumer expectations about the collection and use of personal information, personalized advertising, personalized pricing, and related consumer protection questions. She also studies consumer interactions with artificial intelligence, including how individuals evaluate, verify, and rely on information generated by AI systems, while her litigation experience includes work applying AI and advanced analytical techniques to social media content and other online consumer behavior.

In food, nutrition, health care, and life sciences matters, Ms. O’Laughlin has worked on litigation involving food and beverage labeling, dietary supplements, health-related marketing claims, consumer perceptions of product benefits, and the marketing and commercialization of pharmaceutical and health-related products. Her experience also includes competition and merger matters involving grocery retail and consumer products.

Professor Rossiter is an expert in health economics who has testified or served as an expert in the following areas: competition in the financing and delivery of health services; reimbursement economics, especially for Medicare, Medicare Advantage, and Medicaid; managed care organizations; prescription medicines; survey research; and health information analytics. Professor Rossiter is the former secretary of health and human resources for the Commonwealth of Virginia. In that role, he was responsible for over 15,000 employees in 13 agencies (including 10 state mental hospitals), brought major information technology projects in the Secretariat to national prominence, and made major reforms in Virginia Medicaid. He also served as deputy for policy to the Administrator of the Centers for Medicare and Medicaid Services (CMS). As deputy, he created and directed a new payment system for US hospitals under Medicare, was responsible for the CMS strategic plan, and formulated all agency policy initiatives through the federal legislative process.

Prior to joining the William & Mary faculty, Professor Rossiter was a professor of health administration at Virginia Commonwealth University. He served on the board of regents of the National Library of Medicine, National Institutes of Health; on the board of directors of AcademyHealth; and as chair of the board of directors of the Coalition for Health Services Research, the lobbying arm of AcademyHealth, during the passage of the Affordable Care Act. He has also served on numerous advisory groups, including the National Advisory Council for Healthcare Research and Quality, and is currently a trustee and chair of the Williamsburg Health Foundation. Professor Rossiter is the author or editor of 15 books, and the author of over 50 journal articles on health economics and the role of competition in the financing and delivery of health services.

Professor Ketcham is a health care economist with over two decades of experience researching, teaching, and consulting. His areas of expertise include pharmaceutical advertising and promotion, pharmacy benefit managers, health insurance, consumer decision making, physician decision making, hospital pricing, provider incentive programs and payment methods, fair market valuation, employee benefits, and valuation of changes in morbidity and mortality. From 2022 to 2024, Professor Ketcham took a leave from the W.P. Carey School of Business to serve as senior economic advisor to the employee benefits team of a major high-tech company. He has consulted for and collaborated with several large pharmaceutical firms, Banner Health, CVS Caremark, Symphony Health Solutions, the Centers for Medicare & Medicaid Services, the US Department of Health and Human Services, and the US Environmental Protection Agency. Professor Ketcham’s research has been published in journals such as the American Economic Review, The Review of Economic Studies, the American Journal of Health Economics, and Health Affairs. He has served as principal investigator on multiple grants, including federal government grants to study physician decision making, incentive programs, and provider pricing.

Ms. Hauert is a regulatory expert who specializes in the electric and water utility industries. She has served as an expert witness in rate cases and provided expert testimony for matters before the Arizona Corporation Commission and the Federal Energy Regulatory Commission. In her role at Hauert Consulting, Ms. Hauert draws on her nearly two decades of utility experience to provide strategic consulting services to regulated utilities, including preparing rate cases and rate design, cost-of-service studies, and surcharges. She previously served as vice president of rates and revenues at Arizona Water Company, where she led a $90 million cost recovery strategy and facilitated the acquisition of three small water utilities. Ms. Hauert also held roles at Arizona Public Service, where she oversaw a $3 billion cost recovery strategy and developed a multiyear corporate strategic playbook. She is currently the executive director of the Water Utilities Association of Arizona.

Mr. Grant provides advisory services, privileged consulting, and expert witness testimony, both domestic and international, for energy clients and their counsel. He specializes in matters of competitive analysis, valuation, antitrust, and market design. Mr. Grant has analyzed market structure, firm behavior, and competition in the energy industry, including oil, natural gas, and thermal and renewable power, and advised on climate-related risk factors and environmental, social, and governance (ESG) frameworks. He has submitted testimony related to the value of hydrocarbons, damages stemming from contractual disputes, and liability arising from treaty claims; advised on antitrust matters; and led teams in complex energy-related matters, including mergers and acquisitions, regulatory proceedings, and disputes. Mr. Grant’s recent efforts have focused on valuation of energy, large manufacturing, and public infrastructure assets in emerging markets. He has published articles in journals such as Accounting Today, Global Banking & Finance Review, and the Energy Law Journal. Mr. Grant has previously served as an instructor for the Harvard Institute for International Development, where he taught cost-benefit analysis, project analysis, and microeconomics to officials from utilities, regulatory agencies, and economic development banks in the developing world. He was also a research fellow and research affiliate at Harvard University’s Project on Indigenous Governance and Economic Development, where he analyzed national and tribal policies related to self-governance and economic development.

Mr. Bodington specializes in the business and finance aspects of the electric power industry. He is the founder of a boutique investment banking firm that has provided M&A, financing, and restructuring advisory services to the energy sector for more than 25 years. Mr. Bodington has played a key role in more than 100 transactions with an aggregate value of more than $7 billion. In these engagements, he has led the purchase and sale of interests in power projects; arranged debt and equity financing for energy projects in development, construction, and operation; and advised owners and lenders on various capitalization, value, repayment, restructuring, and management issues. His clients include industrial companies, independent power companies, equity investors, lenders, utility affiliates, and regulated utilities. 

Mr. Bodington is also a seasoned expert witness who has provided testimony for clients on finance and damages issues. Prior to founding Bodington & Company, he spent eight years with Bechtel Group and four years with an international management consulting firm. Mr. Bodington is the author of more than 50 articles on a variety of economic and financial topics relevant to the energy sector. He holds Financial Industry Regulatory Authority (FINRA) Series 7, 24, 63, 79, and 99 licenses.

Professor Hubbard is a leading expert in public economics, corporate and institutional finance, macroeconomics, antitrust, and industrial organization. He has provided trial and deposition testimony in numerous litigation matters, including more than a dozen cases in the Delaware Chancery Court. He has also served as a testifying expert in several high-profile finance- and securities-related cases, as well as on damages issues in antitrust matters. Professor Hubbard has consulted to several government and international agencies, including the US Department of the Treasury, the US International Trade Commission, the US Securities and Exchange Commission, the World Bank, the Board of Governors of the Federal Reserve System, the Federal Reserve Bank of New York, and the Congressional Budget Office. From 2001 to 2003, he served as chairman of the President’s Council of Economic Advisers.

Professor Hubbard has published more than 100 scholarly articles and coauthored several books, including the widely used textbook Money, the Financial System, and the Economy. His commentaries have appeared in Businessweek, The Wall Street Journal, The New York Times, the Financial Times, and The Washington Post, as well as on PBS television and NPR radio business programs. A frequent speaker, Professor Hubbard has presented his research at economic conferences throughout the world.

Ms. Pike applies her expertise in health economics, statistics, and large administrative claims and transaction-level databases to help resolve complex litigation and strategic business questions in a variety of contexts, including matters involving the False Claims Act, Anti-Kickback Statute, and Controlled Substance Act. She has performed economic analyses and presented findings to US Attorney's Office investigators in numerous cases involving allegations of off-label promotion, kickback, and pricing issues. Ms. Pike also applies economic theory and empirical estimation methods in a variety of product liability, breach of contract, intellectual property, and transfer-pricing engagements. She has extensive experience in developing flexible damages models for real-time use in high-stakes negotiations. 

Ms. Pike has been instrumental in developing bespoke suspicious order monitoring programs; building internal analytical programs to assess the risk of theft or diversion; and assisting manufacturers, wholesalers, and pharmacies in responding to government investigations and/or lawsuits related to controlled substance distribution and dispensing. She has managed a range of health care cases involving analysis of future lost profits; economic analysis of physician payment structures under capitation; studies of the cost effectiveness, budget impacts, and direct and indirect costs of illness associated with a variety of diseases; and pricing analyses for large multinational corporations across numerous industries. Ms. Pike has published numerous articles on related topics in health care economics and clinical journals.

Dr. Ugone specializes in the application of economic principles to complex business disputes and is experienced in economic and damages-related analyses. He has provided financial and economic consulting services in cases involving antitrust, breach of contract, class certification, intellectual property, professional negligence, and securities-related issues. Dr. Ugone has frequently evaluated lost profits and valuation-related issues using large databases and complex computer models.

Dr. Ugone has constructed or evaluated damages models that have included such components as lost sales analyses, incremental cost analyses, assessments of profitability, assessments of the capacity to produce additional units, the competitive business environment in which a damage claim is made, claimed lost business value, and claimed reasonable royalties. He has performed economic liability analyses in antitrust matters including defining relevant markets, assessing market power, and evaluating alleged anticompetitive behavior. In consumer product class action matters, Dr. Ugone has addressed economic- and damages-related issues relating to classwide proof of claimed economic harm and price premium claims, including analyses of demand drivers affecting consumer purchase decisions and product pricing patterns observed at wholesale and retail levels. With respect to patent infringement matters, he has performed lost profits-related and reasonable royalty-related analyses.

Dr. Ugone has testified at trial and in deposition approximately 600 times.

Professor Kinch is a drug development expert specializing in cancer, immunological, and infectious diseases. His research focuses on combining cutting-edge science and entrepreneurship to improve public health. During his tenure at Washington University in St. Louis, Professor Kinch founded the Center for Research Innovation in Biotechnology (CRIB). At Long Island University (LIU), he directed CRIB, which uses tools such as the Clinical Drug Experience Knowledgebase (CDEK) to assess trends in drug discovery and development. Professor Kinch also co-founded the Center for Drug Discovery (CDD) to identify and underwrite the university’s most promising drug discovery projects. He has been issued more than a dozen US patents, published more than 100 patent applications, and written several books and book chapters on the commercialization of biopharmaceutical innovation, as well as other aspects of drug development. Professor Kinch has published widely in peer-reviewed journals, including Drug Discovery Today, Science, Cell Chemical Biology, and Biotechnology Law Report, and his research has been profiled in media outlets such as The Wall Street Journal, NPR, CBS News, and The New York Times. Prior to his positions at LIU and Washington University, he was the managing director of the Yale Center for Molecular Discovery. Professor Kinch has also taught at Johns Hopkins University and Purdue University, and held senior scientific research positions at Functional Genetics and MedImmune. He has served on the board of the American Cancer Society and on scientific advisory boards for several biopharmaceutical companies.

Paul E. Greenberg, Director of Analysis Group’s Health Care Practice, consults to pharmaceutical, biotechnology, and medical device companies in complex business litigation matters. Mr. Greenberg’s litigation experience has included performing economic and statistical analyses in support of testifying experts, as well as presenting findings to investigators from US Attorneys’ Offices and the Office of the Inspector General in numerous cases in which violations of the False Claims Act and/or the Anti-Kickback Statute have been alleged. Mr. Greenberg has provided economic consulting support in connection with class certification, liability, and damages in cases involving allegations of product failure, product fraud, antitrust, and/or patent infringement in the biopharmaceutical industry. He has provided strategic assistance to counsel at various key points in litigation, including pretrial discovery, settlement negotiations, and trial preparation. In the area of health economics and outcomes research (HEOR), Mr. Greenberg has undertaken cost-of-illness studies relating to numerous psychiatric and physical disorders, as well as pharmacoeconomic assessments of the cost-effectiveness of drugs based on data gathered in clinical trials and/or administrative claims files. Mr. Greenberg’s work in HEOR has been widely published in leading medical and health economics journals. He currently serves on the editorial boards of PharmacoEconomics, the Journal of Medical Economics, and Expert Opinion on Pharmacotherapy, and he previously served on the editorial boards of Law360’s Life Sciences and Health Care electronic newsletters.

Ms. Hitscherich specializes in corporate acquisitions, leveraged buyouts, exclusive sales and divestitures, takeover defenses, and restructurings. She has served as an expert witness in several complex securities litigations, including matters involving deal structure, valuation, due diligence, custom and usage in the finance industry, and financing alternatives.

Ms. Hitscherich has extensive experience in investment banking and corporate law practice, including as a managing director in mergers and acquisitions with Banc of America Securities, where she was secretary of the Fairness Opinion Review Committee; vice president in mergers and acquisitions with J.P. Morgan & Co., where she was a founding member of the takeover defense team and a senior member of the acquisitions fairness Advisory Review Committee; and as a mergers and acquisitions attorney with Skadden, Arps, Slate, Meagher & Flom.

Ms. Pinheiro has an extensive background in quantitative analysis and data science, with a particular focus on analyzing complex financial data and market behavior, which she has applied across practice areas including traditional and decentralized finance, intellectual property, biostatistics, and antitrust.

In finance, Ms. Pinheiro specializes in matters involving allegations of market manipulation, misleading communications, excessive fees, and complex securities litigation. She has been retained by the US Department of Justice, regulatory agencies, banking institutions, and market exchanges to consult, advise, and testify on matters involving allegations of spoofing and market manipulation, as well as the design and evaluation of corresponding detection approaches. Ms. Pinheiro currently serves on the independent Surveillance Advisory Committee of Kalshi, advising on exchange market integrity and fraud detection matters. Her work also includes the valuation of large portfolios of cryptocurrency assets and the analysis of the market microstructure of digital assets, reflecting both her long-standing experience in the field and early involvement, including Bitcoin mining, Ethereum validation, and certification as a Bitcoin Professional. She has authored expert reports and testified on questions relating to the modeling and calculation of price impact, royalties, and damages.

Beyond financial markets, Ms. Pinheiro applies similar statistical and economic frameworks to a broad range of litigation contexts. She has applied statistical modeling to various intellectual property cases, including patent disputes among smartphone manufacturers, copyright tariff setting for musical works, and patent infringement in the pharmaceutical industry. Her work integrates traditional economic analysis with advanced data science and AI techniques, from evaluating machine learning models in litigation to using generative AI to support the review of large datasets. Additionally, Ms. Pinheiro has worked extensively in antitrust matters, acting as an expert and supporting other experts in class certification and price-fixing matters across industries such as online search, computer chips, liquid-crystal display (LCD) panels, airline ticketing services, gaming, and grocery stores. Her substantial experience analyzing health care data includes clinical trial, registry, and insurance claims data for both litigation and research purposes.

Prior to joining Analysis Group, Ms. Pinheiro served as executive director of the finance group of CIRANO, where she conducted applied research projects in collaboration with private and public partners, including work on hedge funds, style analysis, credit and operational risk, and the development of integrated risk management tools for practical applications.

Read Lisa’s profile

Professor Jena is a health economist, practicing internal medicine physician, and professor of health care policy. His work involves several areas of health economics and policy, including the economics of medical innovation, the economics of physician behavior and the physician workforce, medical malpractice, and the economics of health care productivity. Professor Jena has been retained as an expert in several pharmaceutical and health care industry matters.

A prolific author, Professor Jena is the coauthor of the book Random Acts of Medicine, and he has contributed to more than 150 peer-reviewed articles and articles intended to increase patient understanding, published in outlets including The New England Journal of Medicine and The New York Times. He is a faculty research fellow at the National Bureau of Economic Research and serves on Harvard Medical School’s Standing Committee on Health Policy. Professor Jena is a recipient of the NIH Director’s Early Independence Award to fund research on the physician determinants of health care spending, quality, and patient outcomes, and a recipient of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) New Investigator Award. In 2018, he was listed among 100 great leaders in health care by Becker’s Hospital Review.

Professor Bucklin is an award-winning research specialist in the quantitative analysis of customer purchase behavior. He is an expert on applied choice models in marketing, channels of distribution, and pricing policies. Professor Bucklin has testified or been deposed in numerous cases involving antitrust and damages issues and most recently served as an expert in the Google AdWords litigation. In his current consulting work, Professor Bucklin focuses on quantitative tools to improve corporate marketing decision making and analysis of the variables involved in consumer choice. He has published extensively on topics related to website browsing, e-commerce purchase behavior, and marketing models. His articles have appeared in the Journal of Marketing Research, Marketing Science, the Journal of Retailing, and Marketing Letters: A Journal of Research in Marketing. He also serves on the editorial board of Marketing Letters. Professor Bucklin previously worked as a consultant at Bain & Company and as a business journalist for The Washington Post.

Mr. Gustafson applies his expertise in economics, econometrics, and modeling to litigation, complex business issues, and the analysis of public policy issues. He has worked extensively in the areas of health care, insurance, employment, data privacy, ERISA, finance, intellectual property (IP), commercial damages, and class certification.

In his litigation work, Mr. Gustafson has provided deposition, arbitration, and trial testimony related to the economics of identity theft, physician compensation, the reasonable value of medical services, retirement benefits, employment compensation, lost earning capacity, and commercial damages, and he has critiqued plaintiffs’ proposed damages formulas in several class actions. His case work has involved evaluating claims of excessive investment fees in corporate 401(k) defined contribution plans, assessing the reasonable value of medical services for physicians and hospitals, analyzing health insurance claims to identify instances of alleged fraud and inappropriate billing by hospital providers, and auditing risk-pool reconciliations that set the level of at-risk payments to a hospital group and its physician partners. He has worked on several privacy-related class actions, providing testimony related to the economics of identity theft and damages, as well as supporting privacy, damages, survey, and technical experts.

Mr. Gustafson has worked with clients to perform affirmative pay equity studies and develop methodologies to address identified disparities. He has explored economic issues associated with a wide range of insurance products, including disability, health, life, product liability, and property insurance, as well as variable annuities. Mr. Gustafson also has experience in a variety of ERISA matters, including those related to health care plans, benefits, and insurance claims. Additionally, he has extensive experience assembling and analyzing large, proprietary datasets common in pay equity, insurance, and health care engagements. Prior to joining Analysis Group, Mr. Gustafson was the business manager in Tokyo for an international nonprofit. He also taught economics as a course assistant at the Harvard Kennedy School.

Professor Klausner teaches courses on corporate law, corporate governance, business transactions, and regulation of financial institutions. In recent years, most of his writing has been on corporate governance. He maintains a database on securities class actions and SEC enforcement actions, and has written papers and blog posts based on that database. In addition, Professor Klausner is currently writing a book and producing an online course called Deals: The Economic Foundations of Business Transactions.

Before beginning his academic career, Professor Klausner practiced law in Washington, DC, and Hong Kong. He was a White House fellow from 1989 to 1990, a law clerk for Judge David Bazelon on the United States Court of Appeals for the District of Columbia Circuit in 1981-82, and a law clerk for Justice William Brennan on the United States Supreme Court.

Dr. Van Audenrode is an expert in data analysis and econometrics, labor economics, antitrust and competition policy, and public economics. He has consulted to clients - including law firms and government agencies - in Canada, the US, and Europe. Dr. Van Audenrode’s work includes developing a methodology to value desktop software; he also developed expertise valuing goods as varied as restaurant franchises, executive stock options, or smartphone features. His recent work in public economics includes evaluating the economic rent from hydroelectricity to the Canadian economy and the value of logging rights on the ancestral territory of a Canadian First Nation. In the area of labor economics, his work has included filing an expert report assessing fair compensation for Quebec provincial judges and Quebec prosecutors and advising Quebec’s commission on pay equity. Dr. Van Audenrode has filed expert reports in courts in the US, Canada, Belgium, Germany, France, and the Netherlands, and has testified in Canada and the US. He recently filed a report with the Amsterdam Court of Appeal in support of the settlement reached between Ageas and claimant organizations in the Fortis case, the largest settlement ever reached through the Dutch Collective Settlement Act (WCAM). Dr. Van Audenrode’s scientific research and articles have been published in numerous peer-reviewed academic journals and trade journals. He is a coauthor of the book The Mutual Fund Industry: Competition and Investor Welfare, and is a frequent presenter at industry and academic conferences.

Professor Hochberg specializes in entrepreneurship, innovation, venture capital, and private equity, focusing on venture capital networks, entrepreneurial finance, seed accelerators, and corporate governance and compensation. Her research covers topics such as venture capital investment performance, the effects of networks and syndication on venture capital firms, and investment selection. Professor Hochberg has also explored the private equity investment choices of pension funds and other institutional investors, as well as broad-based option compensation in firms. She is the managing director of the Seed Accelerator Rankings Project, which publishes annual rankings of accelerator programs in the US. Prior to joining the Rice faculty, she held positions at the Kellogg School of Management at Northwestern University and the Samuel Curtis Johnson Graduate School of Management at Cornell University. She has taught courses on entrepreneurial finance and health care innovation, and has served as an associate editor of several finance journals, including the Journal of Empirical Finance and the Journal of Banking and Finance. Professor Hochberg is a recipient of the Ewing Marion Kauffman Prize Medal for Distinguished Research in Entrepreneurship, and a research associate at the National Bureau of Economic Research. Prior to joining academia, she was a software engineer at both established and startup technology companies, and co-founded a startup. Professor Hochberg is an active angel investor and advisor to startups, and a Landmark Fellow with Landmark Partners, a large private equity investor in secondary markets. She is a co-founder of Flywheel Innovation, a corporate innovation advisory firm.

Professor Savitz focuses his epidemiological research on a wide range of public health issues, from the health effects of environmental agents in the workplace and community to a wide range of reproductive health outcomes. He has served as principal investigator on more than three dozen public health studies, including as one of three epidemiologists to evaluate the probable causal link between exposure to perfluorooctanoic acid and the development of certain diseases. Professor Savitz submitted an expert report on behalf of the plaintiffs at the class certification stage of a litigation matter and has consulted on a wide range of issues related to both environmental and reproductive epidemiology. He is the author of more than 300 journal articles and has edited or authored three books, including Interpreting Epidemiologic Evidence: Connecting Research to Applications. Professor Savitz has served as the editor of Epidemiology and the American Journal of Epidemiology, a member of the Epidemiology and Disease Control Study Section of the National Institutes of Health, president of the Society for Epidemiologic Research and the Society for Pediatric and Perinatal Epidemiologic Research, and North American regional councilor for the International Epidemiological Association. He is a member of the National Academy of Medicine and served as vice president for research at Brown University.

Professor Knittel’s research focuses on industrial organization, applied econometrics, and energy and environmental economics. He has provided trial and deposition testimony in a number of litigation matters, including valuing product features in smartphones, PCs, and contact lenses. He has also consulted to Delta Airlines, Ford Motor Company, the US Energy Information Administration, and Korea Electric Power Company. Professor Knittel has authored or coauthored numerous articles on topics such as market structure and product pricing, tacit collusion, and challenges in merger simulation analysis. Examples of his research include articles on the spurious correlation between ethanol production and gasoline prices, unilateral market power in the electricity reserves market, and tacit collusion in credit card markets. His research has appeared in the American Economic Review, the American Economic Journal: Macroeconomics, the American Economic Journal: Economic Policy, The Review of Economics and Statistics, The Journal of Industrial Economics, and The Energy Journal, among other academic publications. He is a former coeditor of the Journal of Public Economics and serves or has served as an associate editor for several other scholarly journals, including the American Economic Journal: Economic Policy, The Journal of Industrial Economics, the Journal of Transport Economics and Policy, and The Journal of Energy Markets. Professor Knittel is a research associate at the National Bureau of Economic Research (NBER) in the Productivity, Innovation, and Entrepreneurship and Industrial Organization programs, and he co-directs the Environment and Energy Economics program.

Jessica Resch is a testifying expert in complex disputes involving valuation, damages, and finance issues, with particular experience in international arbitration, commercial litigation, and shareholder disputes. She has been appointed as an expert in matters before international arbitral tribunals and national courts, including the High Court of Justice of England and Wales, and has provided expert testimony on valuation and damages issues across a wide range of sectors and fact patterns. Her work is especially focused on complex valuation questions, including the assessment of cost of capital, discounts and premia, and the value of derivatives and distressed assets.

Ms. Resch’s case experience includes disputes involving oil and gas developments, project investments, shareholder and joint venture conflicts, failed transactions, breach of warranty claims, FSMA Section 90 and 90A securities litigation, and those relating to private equity, venture capital, and other funding arrangements. She has worked extensively on matters arising in difficult economic and operating environments, including periods of financial crisis, post-pandemic disruption, political instability, civil unrest, and heightened sovereign risk. Prior to joining Analysis Group, Ms. Resch was a partner and co-founder of an economics consulting firm.

Professor Carlson specializes in the marketing management implications of consumer decision-making processes, including the development of brand preferences and the influence of emerging preferences on the decision making process. Though much of Professor Carlson's research explores consumer decision making, he also studies how voters, jurors, and managers make decisions. Over the last 20 years, he has run thousands of surveys, sampling U.S. and international populations.

Professor Carlson has served as an expert in evaluating a survey in a class action matter, consulted on a high profile class action settlement involving consumer deception, and testified before the SEC in an equity trust matter. Professor Carlson's published research can be found in top marketing, psychology, and management journals. He is also the coauthor of Contemporary Brand Management. He blogs for Psychology Today and Forbes, and maintains an active Twitter account (@ProfKurt). While teaching at Georgetown University between 2009 and 2017, Professor Carlson was director of the Georgetown Institute for Consumer Research and co-director of the McDonough School of Business Behavioral Research Lab, and he received the MSB Dean's Distinguished Faculty Research Award and the Decision Analysis Society's Publication Award.

Dr. Vigil is an economic damages expert who applies economics, finance, and statistics to complex commercial and intellectual property (IP) litigation. He has given trial, deposition, and arbitration testimony on damages in patent infringement, trade secret misappropriation, trademark infringement, breach of contract, and false advertising (Lanham Act) matters in US federal courts, before the US International Trade Commission, and in domestic and international arbitrations.

He has quantified reasonable royalties, lost profits, price erosion, unjust enrichment, disgorgement, head-start damages, prejudgment interest, design patent profits, and FRAND royalties for standard essential patents. He has also measured plaintiffs’ losses and defendants’ gains from tortious interference and breaches of contract, non-compete and confidentiality agreements, and fiduciary duty.

Beyond damages, Dr. Vigil has evaluated:

• Commercial success in Hatch-Waxman litigation
• Irreparable harm and causal nexus for injunctions
• Domestic industry and bonding in Section 337 investigations
• The design and reliability of conjoint and other consumer surveys

His litigation and IP valuation work spans these industries:

• Smartphones and consumer electronics
• Telecommunications (4G, 5G, and LTE)
• Semiconductors
• Software and e-commerce
• Pharmaceuticals
• Life sciences tools
• Consumer products
• Medical devices such as surgical staplers, heart valves, and orthopedic implants

He has written on patent damages, lost profits, injunctive relief, marketing, and related topics for publications including the Texas Intellectual Property Law Journal, les Nouvelles, and the Journal of Marketing Research. He has also spoken widely on IP damages and valuation. Dr. Vigil is a Certified Licensing Professional and a member of the American Economic Association, the American Marketing Association, and the Licensing Executives Society. He taught microeconomics and econometrics at the University of Maryland. 

Mr. Klein has more than 30 years of experience in finance, specializing in private equity, alternative asset management, and investment banking. He has served as a testifying expert in litigation involving clients in the private equity industry and has testified in various arbitration proceedings, as well as in state and federal court. Mr. Klein has extensive experience managing equity and debt investments in private and publicly traded companies. In addition to his position at Ingwe Capital, he provides consulting and senior portfolio advisory services to LyonRoss Capital Management, a family office investment advisor that manages a portfolio of hedge fund and private equity investments in excess of $500 million. Previously, Mr. Klein was a managing director in a principal investments group at Lehman Brothers, where he developed strategies and managed teams of investment professionals that generated approximately $500 million in profits. Following the Lehman bankruptcy, he was a managing director in the Lehman Brothers Holdings private equity group, where he was responsible for managing, restructuring, valuing, and liquidating a $1.8 billion portfolio of illiquid assets. Earlier in his career, as co-founder of Templeton Direct Advisors, an international private equity firm, he helped develop, market, and manage several successful private equity funds exceeding $200 million in committed capital. He has served on the boards of directors for several public and private companies.

Dr. Heavner has consulted on a wide variety of litigation topics, including ERISA, securities, and antitrust, and he has analyzed issues related to class certification, liability, and damages. Dr. Heavner’s ERISA casework includes dozens of litigations, including at least six cases in which Analysis Group clients have prevailed at trial. He has written and presented on a variety of topics related to investments and retirement plans. His publications in this area include “Expert Analysis of Plan Losses in ERISA Class Action Litigation” (published in BNA Pension & Benefits Daily).

Dr. Heavner’s securities litigation experience includes directing the support of expert witnesses retained on behalf of mutual fund advisors in many of the largest mutual fund excessive fee actions ever filed, including four such cases that culminated in trial victories for our clients. His other finance and securities casework includes cases involving allegations of securities fraud, imprudent asset management, and investment suitability. In Florida State Board of Administration v. Alliance Capital Management, Dr. Heavner directed the support of expert witnesses retained on behalf of Alliance Capital. This case culminated in a trial in which a Florida jury found Alliance Capital not liable for the losses incurred by the Florida Retirement System pension fund. The National Law Journal declared the verdict one of the top ten defense wins of the year.

Dr. Heavner’s antitrust experience includes matters involving allegations of collusion (including alleged concerted refusals to deal), anticompetitive vertical restraints of trade, predatory pricing, illegal price discrimination, mergers, and standards setting. He has earned Accredited Investment Fiduciary® designation and has been a member of the Analysis Group 401(k) Committee since 2009. He formerly taught economics and finance at Tulane University’s A.B. Freeman School of Business.

Professor Savoldelli is a finance and investment expert with over 25 years of experience analyzing and advising on a wide range of hedge fund-focused issues, including fund performance, portfolio construction, fund administration, due diligence, capital raising, and asset allocation. He served as a chief investment officer for four different institutions: Optima Fund Management, Merrill Lynch, Swiss Bank Corp. Asset Management, and Chase Manhattan Private Bank. In these roles, he oversaw over $80 billion in assets.

Over the course of his investment career, Professor Savoldelli’s responsibilities included selecting hedge funds for the allocation of investor assets, making asset allocation decisions, managing investment portfolios, developing investment policies, and overseeing investment manager adherence to investment strategy and policy. He has deep experience related to the challenging issues hedge fund managers may face, including those related to fiduciary duty, disclosure, liquidation, side-pockets accounts, and valuation of complex and illiquid assets. Additionally, he is knowledgeable about the roles and responsibilities of hedge fund service providers such as prime brokers, marketers, administrators, and auditors.

At Columbia Business School, Professor Savoldelli teaches a course in the M.B.A. program on the investment strategies employed by hedge funds and best practices for the operational aspects of hedge fund management, including fund administration selection, operational risk evaluation, and leverage risk. In addition, he is a contributing editor on Bloomberg Television, commenting on developments from a hedge fund perspective.

Professor Howell’s research focuses on entrepreneurship, private equity, fintech, and innovation. She is a research associate at the National Bureau of Economic Research, a fellow at the Asian Bureau of Finance and Economic Research, and a research fellow at the Institute for Private Capital’s Private Equity Research Consortium. She has testified before the US House Committee on Ways and Means and presented her work before the US Department of Energy, Senate Committee on Small Business and Entrepreneurship, Air Force, and Centers for Medicare & Medicaid Services. Professor Howell is the recipient of the AQR Asset Management Institute Young Researcher Award and the Kauffman Foundation Junior Faculty Research Fellowship, among other awards. She also serves as an associate editor of The Review of Financial Studies and a member of the advisory board to the American Female Finance Committee of the American Finance Association. Prior to joining Harvard Business School, Professor Howell taught finance at the NYU Stern School of Business. Earlier in her career, she was an energy security policy analyst and an energy consultant.

Ms. Samuelson is an expert in antitrust, finance, and valuation, combining more than 30 years of experience applying economic and financial analysis to complex legal disputes with five years of experience as a practicing trial attorney. A key aspect of Ms. Samuelson’s work is the direction of economic analyses for merger review, regulatory investigations, and large private litigations. Working with affiliate David Dranove on behalf of the US Department of Justice, she led the case team that successfully challenged the proposed merger of Anthem and Cigna. She has managed economic analyses related to antitrust issues in more than 100 matters during her career, including numerous government, competitor, and consumer matters on behalf of MasterCard over more than two decades, and on behalf of Microsoft during a similar period. Ms. Samuelson has also provided analysis of issues of class certification, liability, and damages in a broad set of technology- and financial services-related cases, and has analyzed economic issues related to government investigations and mergers involving companies in technology and health care. She has served as an expert in many phases of litigation, including development of economic and financial models; preparation of testimony; development, presentation, and review of pretrial discovery; and critique of economic and financial analyses of opposing experts.

A frequent speaker on topics in antitrust and competition, the role of economics in litigation, and leadership, Ms. Samuelson has presented before a number of legal audiences and at leading academic institutions, including the American Bar Association (ABA)’s Antitrust Section Annual Spring Meeting, the New York State Bar Association (NYSBA)’s Annual Antitrust Law Section Meeting, the Yale School of Management, the University of Chicago Law School, and the MIT Sloan School of Management. She has also participated in numerous legal and economic conferences and seminars. In one representative example, Ms. Samuelson moderated a panel at the US Federal Trade Commission and US Department of Justice joint public workshop on most-favored nation clauses, and subsequently coauthored an article on the program in the ABA Antitrust Section Joint Conduct Committee’s newsletter. Ms. Samuelson was named as one of Global Competition Review’s Women in Antitrust 2016, and she is frequently included in the International Who’s Who of Competition Lawyers and Economists and Euromoney’s Guide to the World’s Leading Competition and Antitrust Lawyers/Economists. She has served as a vice chair of the ABA’s Trial Practice Committee of Antitrust Law.

In addition to her economic consulting work, Ms. Samuelson serves as Chairman of Analysis Group, one of the largest economic consulting firms in the United States. She previously served as CEO and Chairman (between 2016 and 2024), President and CEO (between 2004 and 2016), and as co-CEO (beginning in 1998). Since joining Analysis Group in 1992, Ms. Samuelson has played a key role in the company’s growth and diversification and has brought significant new clients, academic affiliates, and professional staff to the firm. Under her guidance, Analysis Group has been named (by Vault) as one of the top 50 consulting firms in the US for several years running. In Massachusetts, the firm has been consistently named in the annual Top Places to Work ranking by The Boston Globe, and the Top 100 Women-Led Businesses in Massachusetts listing by the Commonwealth Institute and Boston Globe Magazine. Ms. Samuelson is also the chair of the Boston Medical Center Hospital Board of Trustees.

Professor Levinsohn is an expert in antitrust, industrial organization, and econometrics. He has provided expert reports and testimony in several landmark antitrust and regulatory matters, including In re: TFT-LCD (Flat Panel) Antitrust Litigation, In re: Vitamins Antitrust Litigation, In re: New Motor Vehicles Canadian Export Antitrust Litigation, and the Tobacco Master Settlement Agreement proceedings. He has also consulted to numerous foreign governments and international organizations.

Professor Levinsohn conducts research in industrial organization, applied econometrics, international economics, and development economics. He has served on the editorial boards of American Economic Review, The Review of Economics and Statistics, the Journal of International Economics, and the Journal of Economic Literature. Prior to joining the Yale faculty, Professor Levinsohn was the J. Ira and Nicki Harris Family Professor of Public Policy at the Gerald R. Ford School of Public Policy at the University of Michigan.

Mr. Hibbard is an expert on economics, strategy, regulation, and policy in the electric and natural gas industries. He has a comprehensive background merging business development, technical analysis, resource planning and development modeling, economics, and public policy in the energy and environmental fields. Mr. Hibbard has provided technical and strategic advice to government, industry, business, public interest groups, and trade organizations on energy market structure, electric and natural gas infrastructure planning and siting, utility resource solicitation and procurement, emission allocation and environmental policy, renewable resource program design and administration, transmission pricing, climate change policy, utility ratemaking practices, and the transfer of US federal and state emission control programs to other countries.

Prior to joining Analysis Group, Mr. Hibbard was chairman of the Massachusetts Department of Public Utilities. During his tenure, he carried out a forward-looking ratemaking and policy agenda to advance energy efficiency and renewable resources, coordinate regional efforts in the development of energy resources and associated infrastructure, and promote the administration of fair and efficient transmission pricing models in regional and national contexts. He also has provided testimony on resource planning, competitive electricity markets, and transmission pricing in hearings before committees of the Massachusetts legislature and the US House of Representatives, the Federal Energy Regulatory Commission (FERC), and state and regional planning councils. Mr. Hibbard has also served as a member of many energy-related boards and committees.

Mr. Case is an institutional investment expert with significant expertise in the areas of investment governance, asset allocation, portfolio design and implementation, and portfolio analysis and reporting. As a former institutional investment consultant, he worked with a wide range of global clients, including insurers, health care organizations, corporate and public plan sponsors, family offices, and other large asset pools. Mr. Case was a partner at Mercer Investment Consulting, a practice leader at Evaluation Associates, and a senior consultant at Rogerscasey. He led client service teams for large clients, including defined-benefit and defined-contribution plans, insurers and mutual fund families, and registered investment advisors and foundations. As an expert, Mr. Case has evaluated various process-related issues, including the process used to monitor an ERISA plan’s investment advisor and delegated fiduciary. He previously worked as an investment analyst for AT&T’s pension investment team, oversaw the sub-advisory and pension assets of AXA Equitable Life, and managed the strategic relationship team at Putnam Investments. He is a CFA charterholder.

Dr. Koehn specializes in applied microeconomics and finance. He has performed research and given economic testimony in antitrust, regulatory, tax, and other business litigation matters. The author of several publications on topics such as banking and finance, energy economics, and real estate, Dr. Koehn is a former adjunct associate professor of finance at the University of California, Irvine Graduate School of Management.

Professor Jiang is a finance expert whose research focuses on corporate governance, institutional investment, technology, and financial markets. She has published extensively on M&A, as well as corporate finance and governance issues related to control changes. Her work has been published in numerous peer-reviewed journals and featured in major media outlets, including The Wall Street Journal, The Economist, Institutional Investor, Money, Fortune, Businessweek, The New York Times, and the Financial Times. Professor Jiang is the recipient of several awards for research excellence, including from The Journal of Finance, The Review of Financial Studies, and the Journal of Financial Economics, as well as best paper prizes from the Western Finance Association, the Chicago Quantitative Alliance, INQUIRE UK, the Q Group, and the Investor Responsibility Research Center Institute. She has served in editorial roles for several prominent journals, including The Review of Financial Studies, The Journal of Finance, and Management Science.

Professor Jiang is currently the vice president of the American Finance Association. Her three-year term will include a year as president-elect in 2025 and a year as president in 2026. She is also a senior fellow at the Program on Corporate Governance at Harvard Law School, a fellow at the Financial Management Association, a research associate in the Law and Economics and Corporate Finance Programs at the National Bureau of Economic Research, a member of the Committee on Capital Markets Regulation, and the president of the Society for Financial Studies. Prior to joining Goizueta Business School, Professor Jiang was the Arthur F. Burns Professor of Free and Competitive Enterprise and the vice dean for curriculum and instruction at Columbia Business School.

Dr. Weglein is an economist who testifies and supports testifying experts in complex antitrust and securities litigation and in international arbitrations. He has testified on behalf of several large banks (market definition, competitive effects, and damages) in an antitrust case involving municipal bond markets and testified on damages in a major arbitration in the shipping industry. He led a team of consultants working with counsel in Apple’s successful defense against antitrust claims brought by Epic Games. Dr. Weglein co-led a team working on behalf of three traders in the US v. Richard Usher, et al. criminal antitrust case in the foreign exchange market and in subsequent litigation brought by the US Treasury; he also co-led a team of consultants supporting the US Department of Justice (DOJ) in its successful efforts to block the Anthem/Cigna merger. He has worked in private litigation brought by health care providers against payers, several qui tam matters in health care markets, and various matters involving the health care provider and pharmaceutical markets. Dr. Weglein serves as Analysis Group’s representative to the advisory board of the New York International Arbitration Council. He has made presentations to The Knowledge Group, Global Competition Review, the New York State Bar Association, the Moot Alumni Association, and at the DOJ, and has coauthored numerous publications.

Professor Scharfstein is a biostatistician with expertise in the design, monitoring, and analysis of randomized clinical trials and observational studies. His research focuses on methods of reporting the results of clinical studies in which missing or censored data, non-compliance, or non-random treatment assignment may have resulted in selection bias. He has testified at deposition and trial in a number of litigation matters involving drug and medical device safety and efficacy in and outside the US. In addition, Professor Scharfstein regularly consults to the pharmaceutical industry, advising on statistical issues related to the regulatory approval of drugs and medical devices. He has served on multiple data safety monitoring boards for clinical trials, including for the National Institute of Allergy and Infectious Diseases. Professor Scharfstein is the principal biostatistician for the Major Extremity Trauma Research Consortium, which conducts multicenter clinical research studies relevant to the treatment and outcomes of orthopedic trauma sustained in the military. Professor Scharfstein is a fellow of the American Statistical Association, a recipient of the ASA’s George W. Snedecor Award for best paper in biometry, and a recipient of the Harvard T.H. Chan School of Public Health Department of Biostatistics’ Lagakos Distinguished Alumni Award. He has received multiple teaching excellence awards for his classes on probability and statistical theory.

Professor Reibstein’s research focuses on competitive marketing strategies, metrics, and product line decisions, among other topics. He has provided marketing management education and consulting research to companies in the consumer goods, pharmaceutical, and oil and gas industries, among others. His consulting activities have included numerous applications of conjoint analysis and other survey techniques in engagements spanning a wide range of products. Professor Reibstein has submitted expert reports and provided testimony on marketing and marketing research in several litigation matters, including analyses of smartphone features in a patent dispute, health claims in a false advertising dispute, and pharmaceutical detailing in a co-marketing dispute.

His recent work includes assessing strategies to address competitors’ reactions to marketing actions and developing metrics that link marketing decisions to financial consequences, which was published in his book, Marketing Metrics: The Definitive Guide to Measuring Marketing Performance. Professor Reibstein is also the author or coauthor of numerous books and chapters in books on subjects including competitive marketing strategy, global branding, and marketing performance measurement. Professor Reibstein has also written several papers on conjoint analysis and its validity and reliability. His research has been published in leading academic journals, including Marketing Science, the Journal of Marketing Research, and the International Journal of Research in Marketing.  

Professor Reibstein has been honored with more than 30 teaching and publishing awards, including the John S. Day Distinguished Alumni Academic Service Award from Purdue University’s Krannert School of Management. He has served as the chairman of the American Marketing Association board of directors and as the executive director of the Marketing Science Institute.

Ms. Kamerick is an expert in corporate governance, corporate finance, securities law, and mergers and acquisitions (M&A). She has held CFO positions at a number of prominent firms – including BP Amoco (Americas), Heidrick & Struggles, and Houlihan Lokey – and served as a senior financial and legal advisor to major multinational corporations. Ms. Kamerick is a former M&A and securities attorney with Skadden, Arps, Slate, Meagher & Flom. She has significant experience overseeing 401(k) and defined-benefit retirement plans, and chairing defined-benefit retirement plan investment committees. In addition to consulting on financial, strategic, and corporate governance matters, Ms. Kamerick serves on several boards, frequently acting as chair of the audit committee and as the board’s Securities and Exchange Commission (SEC) financial expert. She also serves on the boards of the Legg Mason Closed-End Mutual Funds and the AIG Funds & Anchor Series Trust (a mutual fund complex). Ms. Kamerick is a National Association of Corporate Directors (NACD) Board Leadership Fellow and holds the NACD Directorship certification. She has held several adjunct professorships and lectured on corporate governance and fiduciary duties at numerous universities, as well as in NACD’s Battlefield to Boardroom program for flag officers. Ms. Kamerick is a frequent contributor to Agenda and Directors & Boards. She serves on the Alzheimer’s Association board of directors, as well as its audit and finance committees. In 2020, she was a judge for IR Magazine’s Corporate Governance Awards.

Professor Chalmers is an expert in securities issues, including the trading behavior of investors and the pricing of securities. He has undertaken extensive research in municipal bonds, mutual funds, and trading costs, much of which has been published in leading peer-reviewed academic journals, including The Journal of Finance, the Journal of Financial Economics, and The Review of Financial Studies. In the area of mutual funds, his research with Professors Roger Edelen and Greg Kadlec discovered and explained the source of perverse incentives exploited by so-called market timers in their trading of mutual funds. He has also written about stale pricing problems in equity mutual funds and mutual fund transaction costs, and has collaborated with other mutual fund experts, such as Professors Daniel Bergstresser and Peter Tufano, on research analyzing fund performance across fund marketing channels. He also has extensive expertise in municipal bond pricing and valuation issues. Professor Chalmers' research has been cited in reports by the General Accounting Office and in several testimonies provided before the House Financial Services Committee, as well as being widely referenced in major media outlets. He has authored several expert reports and provided testimony before the US District Court of Wisconsin.

Dr. Kupiec’s research interests include quantitative financial risk measurement, systemic risk, deposit insurance, and the regulation of banking and financial services. At the American Enterprise Institute, he has authored several studies on systemic risk measurement and related regulations, bank stress testing, and bank regulations that follow financial crisis, including their impact on the wider economy. Dr. Kupiec was an associate director of the Division of Insurance and Research and director of the Center for Financial Research (CFR) at the Federal Deposit Insurance Corporation. In these roles, he oversaw research on bank risk measurement that contributed to the development and implementation of regulatory policies, including the international Basel III framework. He also served as chairman of the Research Task Force of the Basel Committee on Banking Supervision. Dr. Kupiec has worked at the International Monetary Fund, Freddie Mac, and J.P. Morgan, as well as for the Division of Research and Statistics at the Board of Governors of the Federal Reserve System. Prior to entering the financial services industry, Dr. Kupiec was an assistant professor of finance at North Carolina State University. He has published articles in several academic journals, including The Journal of Finance, the Journal of Financial Intermediation, the Journal of Financial Stability, the Journal of Financial Services Research, The Journal of Risk, and the Journal of Investment Management.

Dr. Tierney is an expert on energy policy and economics, specializing in the electric and gas industries. She has consulted to companies, governments, nonprofits, and other organizations on energy markets, as well as economic and environmental regulation and strategy. Her expert witness and business consulting services have involved industry restructuring, market analyses, utility ratemaking and regulatory policy, clean energy regulatory policy, transmission issues, wholesale and retail market design, and resource planning and procurement. Dr. Tierney is a former assistant secretary for policy at the US Department of Energy, state cabinet officer for environmental affairs, and state public utility commissioner. She chairs the board of directors of Resources for the Future; serves on the external advisory board of the National Renewable Energy Laboratory; and is a member of the boards of directors of the World Resources Institute, the Alfred P. Sloan Foundation, the Barr Foundation, and other organizations. She has published widely, frequently speaks at industry conferences, and has lectured at many leading universities.

Dr. Siegel's research focuses on the management, strategy, and organizational issues related to cybersecurity, the intelligent integration of information systems, risk management, data analytics, state stability, systems modeling, security of energy delivery systems, and security researchers (aka hackers). He has served as an expert witness and filed expert reports in a number of IT-related litigations for clients such as SAP, JPMorgan, IBM, Kenexa, Fisher Scientific, Ernst & Young, and Macromedia. His expert case work includes matters involving the acquisition of a software firm, software patent litigation and review (e.g., the Patent Trial and Appeal Board case Versata v. SAP), patent infringement and validity analysis, software licensing agreement disputes, and matters involving financial services software and software related to the extraction of data from web pages. Dr. Siegel has published articles on such topics as simulation modeling for cyber resilience, cyber vulnerability markets, data management strategy, architecture for practical metadata integration, heterogeneous database systems, and managing and valuing a corporate IT portfolio using dynamic modeling of software development and maintenance processes. 

Dr. White specializes in health care, transfer pricing and valuation, and general commercial litigation. He combines his expertise in applied microeconomics, statistics, and econometrics with nearly 25 years of experience with client engagements. A diverse range of clients have retained Dr. White to assist in all stages of the litigation cycle – including advising on discovery issues, expert report preparation, and preparation for deposition and trial. He has worked on general commercial litigation matters such as allegations of false advertising and breach of contract, investigations into alleged off-label promotion of prescription drugs, and the economic impact of generic drug entry/substitution. Additionally, he has also analyzed economic issues relevant to class certification and quantification of damages.

Dr. White has managed numerous commercial litigation matters, supporting academic and industry specialists with expertise in industrial organization, statistics, health economics, and marketing. His tax and transfer pricing work has evaluated the arm’s length nature of pricing in intercompany transactions, and the estimation of useful economic lives for various tangible and intangible assets. In addition to his litigation work, Dr. White’s health economics engagements have included the development of empirical models for evaluating factors to help identify patients at risk of prescription opioid abuse, as well as the estimation of societal economic costs of prescription opioid abuse.

An active researcher, Dr. White’s publications have focused on specific health economics issues, such as the economics of prescription opioid abuse and the evaluation of the impact of biosimilar approval on the litigation landscape. He has presented and participated in a number of industry conferences. Dr. White is an adjunct faculty member in the Department of Economics at Northeastern University, where he teaches courses on applied microeconomics and applied econometrics.

Dr. Yang is an expert in health economics and outcomes research (HEOR), with extensive experience in developing comprehensive HEOR strategies to support products throughout their entire life cycles. As part of her diverse portfolio of HEOR case work, she has developed robust launch strategies; generated real-world data (RWD); and created clinical, economic, and humanistic evidence to support product value propositions. Notably, Dr. Yang has led case teams in preparing submissions to health technology assessment (HTA) agencies across the world, including those in the UK, France, Germany, Norway, Australia, Canada, and Japan. She has also conducted numerous studies across various therapeutic areas – such as autoimmune diseases, infectious diseases, diabetes, blood disorders, oncology, women’s health, and rare diseases – and worked across diverse treatment paradigms, including one-time interventions involving cell and gene therapies, as well as recurrent treatment regimens. Dr. Yang’s work has been widely published in peer-reviewed journals and featured at health care conferences.

Read Hongbo's profle

Professor Riddiough is best known for his work on real options, mortgage pricing and strategy, REITs, and land use regulation. He has served as an expert in numerous real estate-related matters, in which he has testified on appraisal and the value of distressed mortgages. Professor Riddiough has consulted to numerous organizations, including the US Department of Housing and Urban Development, GMAC, Wells Fargo, Coldwell Banker Commercial, The Equitable Life Assurance Society, and the State of Wisconsin Investment Board. He has published more than 40 scholarly articles. He has served on the boards of directors of several organizations, including ArCap REIT, EquiBase Capital Partners, and the American Real Estate and Urban Economics Association. Professor Riddiough is the recipient of best dissertation and best paper awards in real estate economics, and is a fellow at the Real Estate Research Institute and a past fellow at the Homer Hoyt Institute. He teaches courses in real estate finance, real estate capital markets, and microeconomics.

Professor Keller is a marketing expert who specializes in the application of consumer psychology, information processing, and choice behavior to complex litigation matters involving claims of consumer confusion, false advertising, trademark infringement, and product liability, among other topics. She studies the application of social marketing principles and behavioral theory in consumer and employee contexts, with a focus on designing and implementing consumer communication programs. Professor Keller’s research has been used to assess consumer behavior and decision making and address how consumers incorporate and respond to information across a variety of settings and industries, including pharmaceuticals, health care, financial services, consumer products, law, employee benefits, and insurance. She regularly collaborates with academic and industry experts to inform government-sponsored research on physician and patient decision making for organizations such as the National Institutes of Health, the National Cancer Institute, and the National Institute on Aging.

Professor Keller has consulted to firms on US Food and Drug Administration (FDA) and Federal Trade Commission (FTC) matters and worked on behalf of several government agencies, including the US Department of the Treasury and the Centers for Disease Control and Prevention (CDC). Her work has been published in several marketing journals, and she has also served on numerous journal editorial review boards. She has earned awards for designing effective communications related to health and savings from the Marketing Science Institute and the National Endowment for Financial Education, among others. Professor Keller’s research on decision making was cited by the Social and Behavioral Sciences Team’s 2015 Annual Report for the White House on the use of behavioral science in the design of federal programs and policies. Professor Keller is a fellow of the Association for Consumer Research.

Mr. Hutchings’ economics expertise spans a wide array of topics, including tax and transfer pricing, securities and finance, valuation and damages, and antitrust. Deeply experienced in litigation, international arbitration, and investigations, he has led case teams, conducted economic and financial analyses, estimated damages and liability, and performed valuation analyses in complex matters across many jurisdictions, including the US, Canada, the UK, the EU, Latin America, and Australia.

In tax controversy and transfer pricing matters, he has assisted expert witnesses and attorneys for both taxpayers and taxing authorities in jurisdictions around the world. Mr. Hutchings has analyzed intercompany financings for both debt/equity characterization and debt pricing questions, valued closely held corporations, studied issues of cost allocations between related parties, and assessed arm’s-length pricing in a variety of contexts. For example, he has worked with financial institutions on allocating losses amongst subsidiaries, studied the sources of value for consumer packaged goods, priced related party transactions for pharmaceutical products, and worked with medical device manufacturers on transfer pricing between related parties. Mr. Hutchings has provided expert reports on tax dispute and transfer pricing issues for both planning and litigation. He has also applied transfer pricing principles in non-tax disputes such as assessing fairness in corporate transactions between related parties.

In antitrust and competition matters, Mr. Hutchings has analyzed anticompetitive effects, evaluated potential remedies, examined the economics of platform markets, and assisted in the preparation of analysis and testimony before courts and government regulators, such as the US Federal Trade Commission (FTC).

In addition, he has quantified harms and foregone benefits, and valued natural resources and treaty entitlements, in several disputes between Canadian First Nations and the Crown, both testifying at trial and consulting to reach pre-dispute resolutions. He has also quantified damages arising from tortious interference, breach of contract, and other contractual and extra-contractual remedies, and provided valuation analyses in numerous commercial disputes.

Dr. Chan is a practicing internal medicine physician and an economist. His research draws on industrial organization, labor economics, and applied econometric principles to study how technology and information are used in health care, and how they affect productivity and patient care. Dr. Chan’s government service includes roles as entrepreneur in residence in the White House Office of Science and Technology Policy, staff fellow in the Food and Drug Administration’s (FDA’s) Center for Drug Evaluation and Research, and medical device fellow in the FDA’s Center for Devices and Radiological Health. He has published on health economics and policy in medical and economics journals such as The New England Journal of Medicine, the Journal of Political Economy, Econometrica, and The Quarterly Journal of Economics. Dr. Chan presents frequently at national and international conferences and has received numerous grants and awards, including the National Institutes of Health Director’s High-Risk, High-Reward Early Independence Award, and a Marshall Scholarship. He is a faculty research fellow at the National Bureau of Economic Research. Dr. Chan is also co-director of the US Department of Veteran Affairs Queri Center for Policy Evaluation.

A specialist in finance and securities, Dr. Wong has managed teams supporting academic and industry affiliates in litigation matters involving securities fraud, damages, bankruptcy, suitability analysis, portfolio management, mortgage lending practices, accounting analysis, market manipulation, and financial statement analysis. He has extensive experience analyzing fixed-income instruments, structured finance instruments, and credit derivatives. Dr. Wong has worked on and provided testimony in government regulatory investigations. His recent engagements include work in legal disputes related to structured finance instruments, including residential mortgage-backed securities (RMBS) and collateralized debt obligations (CDOs); securities lending; mutual funds and other commingled investment pools; corporate governance; and investment suitability claims. He has also worked on valuation, class certification, and intellectual property matters.

Dr. Wong joined Analysis Group from Chicago Partners in 2006, and has played an instrumental role in the development and growth of the firm’s Chicago practice. He is a member of the American Finance Association and has published research on bankruptcy and the financing of new firms.

Read Andy's profile

Professor Laby is an expert in corporate law, securities regulation, the regulation of investment management, and the fiduciary obligation. He has been retained as a consultant and expert witness, and he has testified in federal and state court, in arbitration hearings, and in Securities and Exchange Commission (SEC) administrative proceedings in matters involving issues such as investment suitability, fiduciary duty, the roles and responsibilities of broker-dealers and investment advisors, and conflict-of-interest transactions. Professor Laby has also opined on corporate law topics such as directors’ duties, insider trading, and piercing the corporate veil. He is coauthor of a multi-volume treatise titled The Regulation of Money Managers: Mutual Funds and Advisers. He has published book chapters and articles on topics such as the regulation of financial firms, the regulation of retirement advisors, and the duties and obligations of financial market participants in publications such as the Washington Law Review, the Florida Law Review, the Boston University Law Review, the Tulane Law Review, the Review of Banking and Financial Law, and The Business Lawyer. Professor Laby is a co-director of the Rutgers Center for Corporate Law and Governance and a director of the Japan Smaller Capitalization Fund, a closed-end management investment company listed on the NYSE. He also serves on the Financial Industry Regulatory Authority (FINRA) National Adjudicatory Council, a committee that reviews initial decisions in FINRA disciplinary and membership proceedings. Previously, Professor Laby served on the board of directors of the Certified Financial Planner Board of Standards, as chairman of the board of trustees of the SEC Historical Society, and as a member of an American Bar Association (ABA) task force that prepared the fourth edition of the ABA Fund Director’s Guidebook. Before joining the Rutgers faculty, Professor Laby served as SEC assistant general counsel, where he was responsible for investment management and international matters, and was in private practice.

Professor Simonson is an expert in survey methods, behavioral decision making, buyer behavior, consumer evaluation of brands and promotional offers, and marketing management. His research includes experimental studies on the effect of survey methods on likelihood-of-confusion estimates and examines topics such as how consumers make product choices in the digital marketplace, how information gleaned from customer surveys can be misleading, and how consumer decision making impacts marketing practices. Professor Simonson has served as an expert witness in matters involving surveys, trademarks, buyer behavior, the impact of product and service features on buyers’ choices, false advertising, branding, and other marketing issues. He has consulted to clients in a wide range of industries. He is a coauthor of the book Absolute Value: What Really Influences Customers in the Age of (Nearly) Perfect Information.

Professor Simonson has also published numerous articles on topics such as the impact of product features, product and service evaluations, trademark confusion, buyer decision making, and survey methods. His research has won many awards, including two O’Dell awards for research that has made a “significant, long-term contribution” to the field of marketing. Professor Simonson is also a lifetime fellow of the Association of Consumer Research for his impact on the scholarly study of consumer behavior. He received an honorary doctorate from the University of Paris II (Sorbonne Universities). He serves on the editorial boards of several leading publications and is the coeditor of Consumer Psychology Review. At Stanford, Professor Simonson has taught M.B.A. courses on marketing management, marketing to businesses, technology marketing, and applied behavioral economics, as well as Ph.D. courses on buyer behavior, surveys, consumer research methods, and behavioral economics.